Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
1 finding from 1 review
Serious adverse events ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review